Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00430170
Status:
COMPLETED
Last Update Posted:
2008-07-29
First Post:
2007-01-31
Brief Title:
Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury
Sponsor:
Radboud University Medical Center
Organization:
Radboud University Medical Center
Study Overview
Official Title:
Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury
Status:
COMPLETED
Status Verified Date:
2008-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this project is to explore the interaction between caffeine and dipyridamole on ischemia-reperfusion injury in the forearm
Detailed Description:
Dipyridamole has been proven to reduce targeting of Annexin A5 in responses to ischemic exercise indicating protection against ischemia-reperfusion injury in humans pharmacological preconditioning Dipyridamole increases the endogenous adenosine level by inhibition of the nucleoside transporter ENT-1 Activation of the adenosine receptor protects against ischemia-reperfusion injury We hypothesize that endogenous adenosine mediates the protective effect of dipyridamole against ischemia-reperfusion injury Therefore the adenosine receptor antagonist caffeine will reduce the benefit of dipyridamole on forearm ischemia-reperfusion injury
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None